Applications published 11 March 2009

Extracts of Aphanizomenon flos aquae and nutritional, cosmetic and pharmaceutical compsns containing the same
Nutratec 2032122*

Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
Polichem 2032123*

Multiparticulate osmotic delivery system
Bioavail Laboratories 2032124*

Ropinrole-containing pharmaceutical compsns in the form of a gel, uses thereof
Jazz Pharmaceuticals 2032125*

Rabeprazole formulation
Lek Pharmaceuticals 2032126*

Treating psychological conditions using muscarinic receptor M1 antagonists
Theracos 2032127*

Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
Schwarz Pharma 2032128*

Compsns of phenylephrine useful for treatment of respiratory illness
Procter & Gamble 2032129*

• Ophthalmic compsns for treating ocular hypertension
Merck & Co 2032130*

• Method of treatment
SmithKline Beecham 2032131*

• Compsns comprising tegaserod alone or in combination with a proton pump inhibitor for treating or prevention of gastric industry
Novartis; Novartis Pharma 2032132*

• Compsns and kits comprising a melatonin component and an omega-3-fatty acid component
Procter & Gamble 2032133*

• Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
Genzyme 2032134*

• Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
Helicon Therapeutics 2032135*

• Compsns and kits comprising a melatonin component and a chondroprotective component
Procter & Gamble 2032136*

• Compsns comprising nanoparticulate naproxen and controlled release hydrocodone
Elan Pharma International 2032137*

• Aminothiazole derivatives as inhibitors of mark
Merck Sharp & Dohme 2032138*

• Compsns comprising nanoparticulate meloxicam and controlled release hydrocodone
Elan Pharma 2032139*

• Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1 (2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
Istituto di Richerche di Biologia Molecolare P. Angeletti 2032140*

• Inhibitors of janus kinases
Merck 2032141*

• Novel compounds
Glaxo Group 2032142*

• Treating cancer with cardiac glycosides
University of Louisville Research Foundation 2032143*

• Methods and immune modulatory nucleic acid compsns for preventing and treating disease
Bayhill Therapeutics 2032144*

• Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
The Board of Regents of the University of Texas System 2032145*

• Methods and compsns related to TR4
University of Rochester 2032146*

• COX-2 inhibitor
Cambridge Scientific 2032147*

• Compsn containing Lactobacillus sp. and a cannabinoid receptor and/or an opioid receptor agonist
Danisco 2032148*

• Method and systems for using biopolymer-based beads and hydrogels
FMC Biopolymer 2032149*

• Novel enterococcus and streptococcus strains and bacteriocins
The United States of America, as represented by the Secretary of Agriculture; State Research Centre for Applied Biotechnology, Moscow 2032150*

• Combination therapy method and formulation
The Regents of the University of California 2032151*

• Use cathelicidin antimicrobial protein (HCAP18) as anticancer agent
Lipopeptide 2032152*

• Use of thymosin alpha 1 for preparing a medicament of stage IV malignant melanoma
Sigma-Tau Industrie Farmaceutiche Riunite 2032153*

• Stabilised insulin-like growth factor polypeptides
Novartis 2032154*

• Stabilised insulin-like growth factor polypeptides
Novartis 2032155*

• Compsns and methods for the delivery of oxygen
The Regents of the University of California 2032156*

• High frequency application of neurotoxic component of botulinum toxin
Merz Pharma 2032157*

• Adjuvant compsns
Mitchell, Timothy; Cowan, Graeme; Douce, Gillian 2032158*

• Combination of FgammaRIIB antibodies and CD20-specific antibodies and methods of use thereof
MacroGenics 2032159*

• Vaccine
GlaxoSmithKline Biologicals 2032160*

• Vaccine
GlaxoSmithKline Biologicals 2032161*

• Herv-K antigens, antibodies, and methods
Board of Regents, The University of Texas System 2032162*

• Adjuvant-sparing multi-dose influenza vaccination regimen
Novartis 2032163*

• Method for the preparation of specific antigens against saccharidic antigens
Bracco Imaging 2032164*

• Bioactive purified HSPE7 compsns
Nventa Biopharmaceuticals 2032165*

• Compsns and methods for diagnosing and treating cancer
Oncomed Pharmaceuticals 2032166*

• A novel target in the treatment of cytokine release syndrome
CellAct Pharma 2032167*

• Capecitabine combination therapy
Ariad Gene Therapeutics 2032168*

• Methods and compsns for the treatment and prevention of Staphylococcus aureus infections with opuc operon interaction with trap
Tufts University 2032169*

• Anti-inflammatory compsn comprising glycine and lactoferrin and the use thereof
NV Nutrica 2032170*

• A process for manufacturing a delivery system for active components as part of an edible compsn
Cadbury Adams 2032171*

• Leptomycin derivatives
Sanofi-Aventis 2032172*

• Helper virus-free herpes virus amplicon particles and uses thereof
University of Rochester 2032173*

• Method and device for inactivating viruses and/or bacteria in liquid media, in particular in blood plasma and preserved serum
Drk-Blutspendedienst Baden-Wuerttemberg-Hessen 2032174*